320 related articles for article (PubMed ID: 9425933)
21. Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy.
Nakamura K; Yoneda M; Kimura A; Tamori K; Yokohama S; Sato Y; Kato T; Hasegawa T; Saito H; Aoshima M; Fujita M; Makino I
J Gastroenterol Hepatol; 1996 Apr; 11(4):385-90. PubMed ID: 8713707
[TBL] [Abstract][Full Text] [Related]
22. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
[TBL] [Abstract][Full Text] [Related]
23. Ursodeoxycholic acid in the treatment of chronic liver disease.
Cirillo NW; Zwas FR
Am J Gastroenterol; 1994 Sep; 89(9):1447-52. PubMed ID: 8079918
[TBL] [Abstract][Full Text] [Related]
24. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
Marschall HU; Wagner M; Zollner G; Fickert P; Diczfalusy U; Gumhold J; Silbert D; Fuchsbichler A; Benthin L; Grundström R; Gustafsson U; Sahlin S; Einarsson C; Trauner M
Gastroenterology; 2005 Aug; 129(2):476-85. PubMed ID: 16083704
[TBL] [Abstract][Full Text] [Related]
25. Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator (Cftr) in mice.
Bodewes FA; Wouthuyzen-Bakker M; Bijvelds MJ; Havinga R; de Jonge HR; Verkade HJ
Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(9):G1035-42. PubMed ID: 22301109
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the effects between ursodeoxycholic and chenodeoxycholic acids on liver function and structure and bile acid composition in the Rhesus Monkey.
Sarva RP; Fromm H; Farivar S; Sembrat RF; Mendelow H; Shinozuka H; Wolfson SK
Gastroenterology; 1980 Oct; 79(4):629-36. PubMed ID: 7409382
[TBL] [Abstract][Full Text] [Related]
27. Study of human isoursodeoxycholic acid metabolism.
Marschall HU; Roeb E; Yildiz Y; Busch N; Nguyen H; Purucker E; Thomas HG; Matern S
J Hepatol; 1997 Apr; 26(4):863-70. PubMed ID: 9126801
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of cholestatic liver diseases with phenobarbital and ursodeoxycholic acid].
Stiehl A
Z Gastroenterol; 1993 Feb; 31 Suppl 2():129-30. PubMed ID: 7483696
[TBL] [Abstract][Full Text] [Related]
29. Lithocholic acid as a biomarker of intrahepatic cholestasis of pregnancy during ursodeoxycholic acid treatment.
Lucangioli SE; Castaño G; Contin MD; Tripodi VP
Ann Clin Biochem; 2009 Jan; 46(Pt 1):44-9. PubMed ID: 19103957
[TBL] [Abstract][Full Text] [Related]
30. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
31. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy.
Meng LJ; Reyes H; Axelson M; Palma J; Hernandez I; Ribalta J; Sjövall J
Hepatology; 1997 Dec; 26(6):1573-9. PubMed ID: 9398000
[TBL] [Abstract][Full Text] [Related]
32. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
33. Effects of taurine and ursodeoxycholic acid on liver function tests in patients with cystic fibrosis.
Colombo C; Battezzati PM; Crosignani A; Assaisso M; Ronchi M; Giunta A
Acta Univ Carol Med (Praha); 1990; 36(1-4):148-51. PubMed ID: 2130679
[TBL] [Abstract][Full Text] [Related]
34. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
35. Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy.
Setchell KD; Heubi JE; Bove KE; O'Connell NC; Brewsaugh T; Steinberg SJ; Moser A; Squires RH
Gastroenterology; 2003 Jan; 124(1):217-32. PubMed ID: 12512044
[TBL] [Abstract][Full Text] [Related]
36. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
[TBL] [Abstract][Full Text] [Related]
37. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
38. Natural history of liver disease in cystic fibrosis.
Lindblad A; Glaumann H; Strandvik B
Hepatology; 1999 Nov; 30(5):1151-8. PubMed ID: 10534335
[TBL] [Abstract][Full Text] [Related]
39. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps.
Batta AK; Salen G; Holubec H; Brasitus TA; Alberts D; Earnest DL
Cancer Res; 1998 Apr; 58(8):1684-7. PubMed ID: 9563483
[TBL] [Abstract][Full Text] [Related]
40. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
